Although androgen insufficiency is a clinical symptom of multiple disease states in men, androgen is considered to be the primary hormone underlying sexual desire in both men and women. Testosterone, along with estrogen and progesterone, is elemental in the development of increased libido in females. Coupled with the dearth of approved treatments and the lack of knowledge and clinical research on the disease states themselves, a wide gap has been left in the care of female patients. In addition, unconfirmed doses lead to many unwanted potential adverse effects, and transference issues still pose an issue. Measures can be taken to prevent transference, as with men, and it is crucial that women receiving testosterone therapy receive appropriate and necessary counseling. Androgen therapy in women is an important topic and has been recognized as such by several groups in the past few years. It is recommend that the medical community delve deeper Boldenone undecylenate not only Boldenone undecylenate therapy, but also the conditions requiring it. Additional information on normal laboratory values and assessments of the safety and efficacy of testosterone therapy in all populations of women will greatly improve our knowledge base.